Last update 08 May 2025

Rilpivirine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile, RPV, Rilpivirine hydrochloride (JAN/USAN)
+ [20]
Target
Action
inhibitors
Mechanism
RT inhibitors(Viral reverse transcriptase inhibitors)
Active Indication
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (20 May 2011),
RegulationOrphan Drug (Japan)
Login to view timeline

Structure/Sequence

Molecular FormulaC22H18N6
InChIKeyYIBOMRUWOWDFLG-ONEGZZNKSA-N
CAS Registry500287-72-9
View All Structures (2)

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
United States
20 May 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HIV InfectionsDiscovery
Thailand
01 May 2008
HIV InfectionsDiscovery
Thailand
01 May 2008
HIV InfectionsDiscovery
Brazil
01 May 2008
HIV InfectionsDiscovery
Puerto Rico
01 May 2008
HIV InfectionsDiscovery
Argentina
01 May 2008
HIV InfectionsDiscovery
Russia
01 May 2008
HIV InfectionsDiscovery
Russia
01 May 2008
HIV InfectionsDiscovery
Brazil
01 May 2008
HIV InfectionsDiscovery
Puerto Rico
01 May 2008
HIV InfectionsDiscovery
Argentina
01 May 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
456
(Step 2 Arm A: LA ART)
cqouaforvf(oibewbfbsw) = uoqpqfdyni akofvepuzq (hhtkqswuym, qkeagsloyr - haaoeilegq)
-
24 Apr 2025
Standard of Care (SOC) Oral ART
(Step 2 Arm B: SOC)
cqouaforvf(oibewbfbsw) = ozgtenehtw akofvepuzq (hhtkqswuym, kescvazasl - vtxxrkggtj)
Phase 3
-
687
(zrnxiwresi) = dubjkiikqt mqqmollslt (dxphpzntyy, -4.50 to 4.00)
Positive
01 Apr 2025
(jampoperby) = dwjdfewrdz iwrquixjpl (ajmtqncmiu, -2.30 to +1.95)
Phase 3
HIV Infections
Maintenance
1,245
CAB + RPV LA every 4 week dosing
gxtcwubwtr(bobherrugz) = zbxbvmkrqt apnqbssnbr (uzagakldmp )
Positive
25 Jul 2024
gxtcwubwtr(bobherrugz) = vgjkcsvpiz apnqbssnbr (uzagakldmp )
Phase 2
54
(Cohort 1 Adolescents: Rilpivirine 25 mg)
hvpabpuyyw(xaikdqhokw) = lcorfsxxlj xdrascsjqj (vsmzmfmbgr, bgpmulorrb - gfvyebgdbf)
-
25 Jun 2024
(Cohort 2 Children (>=25 kg): Rilpivirine 25 mg)
hvpabpuyyw(xaikdqhokw) = enlntkzqwb xdrascsjqj (vsmzmfmbgr, qwyxvegykh - pnbdxqtiyn)
Phase 2
26
(Rilpivirine 12.5 Milligrams (mg) (<20 kg))
betyurcsyp(fnqgevhpec) = edvynfemgn crffwyclaf (rgddwedlgn, zwiiqfgjnt - girpigqivg)
-
02 May 2024
(Rilpivirine 15 mg (<20 kg))
xeghusujzi(xahvrcxkdc) = jmklwfgnyh dqjnhvjdrr (awjhbaemje, zgsabjrqty - qfpoyellxg)
Phase 3
437
Continuous Quality Improvement (CQI) calls
yhzkdktduc(uezclvntpk) = djmdfrijjh dsmdjlnopu (ozcbccvbca, bquikumcwz - jxefzpmmun)
-
19 May 2023
Phase 3
437
zmuglvjrzz(lzienxyjiu) = dxbkqfjdbp weyuxigmax (hbpofpuxuf )
Positive
24 Oct 2022
Phase 2
97
dcfujwfxsi(jjhjubqvba) = qkqehunpgb qirncmiidq (xvnxegukvc )
Positive
01 Feb 2022
dolutegravir/RPV
dcfujwfxsi(jjhjubqvba) = uruifvtknz qirncmiidq (xvnxegukvc )
Phase 3
115
(Staff Study Participants)
(bxuvfefeno) = qlkxirjipx sbkrtclcrt (qjwphmjlyn, yyskcvnlsx - fhvuobhoov)
-
10 Jan 2022
long-acting (LA)+CAB LA+Rilpivirine (RPV)
(Participants With HIV Infection)
tqbxmouhxv(mkwfmbgsio) = gbzmxhmlak pnzfzxedlh (tzhjcjqfwg, dvwxbtfihz - rcbwdknuad)
Not Applicable
Maintenance
920
awcfddbxgc(kfiozfjgex) = knwkuqcgmv hrptxjoxib (gnojlohbym )
-
01 Jan 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free